ANDA 62269, held by Epic Pharma LLC. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 62269 (Doxycycline Hyclate), held by Epic Pharma LLC, was first approved by FDA on Nov 8, 1982, with 30 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 8, 1982 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 100MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 50MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Mar 31, 2025 | Supplement 51Labeling · Standard review | Approved | None posted |
| Sep 8, 2020 | Supplement 43Labeling · Standard review | Approved | None posted |
| Sep 8, 2020 | Supplement 41Labeling · Standard review | Approved | None posted |
| Sep 8, 2020 | Supplement 38Labeling · Standard review | Approved | None posted |
| Sep 8, 2020 | Supplement 31Labeling · Standard review | Approved | None posted |
| Sep 8, 2020 | Supplement 29Labeling · Standard review | Approved | None posted |
| Jul 14, 2016 | Supplement 27Manufacturing | Approved | None posted |
| Oct 27, 2015 | Supplement 28Labeling · Standard review | Approved | None posted |
| Jun 30, 2015 | Supplement 24Labeling · Standard review | Approved | None posted |
| May 19, 2014 | Supplement 22Labeling · Standard review | Approved | None posted |
| Nov 22, 2013 | Supplement 21Manufacturing | Approved | None posted |
| Apr 18, 2003 | Supplement 20Labeling | Approved | None posted |
| Apr 18, 2003 | Supplement 18Labeling | Approved | None posted |
| Sep 26, 2002 | Supplement 17Manufacturing | Approved | None posted |
| Jul 24, 2002 | Supplement 15Manufacturing | Approved | None posted |
| Jun 28, 2002 | Supplement 16Manufacturing | Approved | None posted |
| Feb 8, 2002 | Supplement 14Manufacturing | Approved | None posted |
| Dec 6, 2001 | Supplement 13Manufacturing | Approved | None posted |
| Nov 2, 2001 | Supplement 7Manufacturing | Approved | None posted |
| Oct 17, 2001 | Supplement 12Manufacturing | Approved | None posted |
| Oct 17, 2001 | Supplement 11Manufacturing | Approved | None posted |
| Oct 17, 2001 | Supplement 10Manufacturing | Approved | None posted |
| Oct 17, 2001 | Supplement 9Manufacturing | Approved | None posted |
| Sep 24, 2001 | Supplement 8Manufacturing | Approved | None posted |
| Nov 12, 1997 | Supplement 6Manufacturing | Approved | None posted |
| Oct 7, 1994 | Supplement 5Labeling | Approved | None posted |
| Jul 29, 1994 | Supplement 2Manufacturing | Approved | None posted |
| Aug 31, 1993 | Supplement 4Labeling | Approved | None posted |
| Aug 31, 1993 | Supplement 3Labeling | Approved | None posted |
| Nov 5, 1992 | Supplement 1Manufacturing | Approved | None posted |
| Nov 8, 1982 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters